In the future, by detecting the levels of Apelin and Vaspin, we can effectively evaluate and understand the development and progression of HT, confirm the prognosis of patients, and take early and timely intervention measures to protect the health of patients in clinical practice. This evidence concerns the gene APLN and hematocrit.